Inside information: Orion upgrades full-year outlook for 2025
ORION CORPORATION
STOCK EXCHANGE RELEASE – INSIDE INFORMATION
9 JULY 2025 at 13.00 EEST
Inside information: Orion upgrades full-year outlook for 2025
Orion Corporation upgrades the full-year outlook for 2025 both for the part regarding net sales and operating profit. Orion’s product sales and royalty income have increased faster than expected during the first half of 2025, and this good development is anticipated to continue during the remainder of the year. Due to these reasons, Orion upgrades the full-year outlook for 2025.
The outlook for 2025 does not include any material milestone payments. Orion is entitled to receive from its partner Bayer one more milestone payment related to the sale of the Nubeqa®, amounting to EUR 180 million. According to Orion's current estimate, the milestone payment could be recorded in 2026 or even already in 2025. There is a lot of uncertainty about the timing of the milestone payment, which is why it has not been included in the 2025 outlook estimate.
New full-year outlook, provided on 9 July 2025
Net sales are estimated to be EUR 1,630 million to EUR 1,730 million.
Operating profit is estimated to be EUR 400 million to EUR 500 million.
Previous full-year outlook, provided on 25 February 2025
Net sales are estimated to be EUR 1,550 million to EUR 1,650 million.
Operating profit is estimated to be EUR 350 million to EUR 450 million.
Orion Corporation
| Liisa Hurme President and CEO | Mikko Kemppainen General Counsel | |
Contact person:
Tuukka Hirvonen, Head of Investor Relations
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.
